Abstract: This application provides a communication method and a communications apparatus. The method includes: receiving, by a terminal device, conditional handover configuration information from a first network device, where the first network device is a network device to which a serving cell belongs, and the serving cell is a cell that currently accessed by the terminal belongs; and determining, by the terminal device, a first target cell based on the conditional handover configuration information.

Abstract: A liquid yeast one- and two-hybrid high-throughput library screening method and use thereof changes the screening of solid medium to liquid culture solution screening, avoiding a large number of plate coating work, and avoiding the tedious work of identifying single colonies one by one, which not only saves experiment time, but also reduces the cost and workload; at the same time, the present invention also combines high-throughput sequencing technology to improve the analysis throughput of yeast hybridization screening work, and can also improve the automation level of analysis, and can greatly reduce false negatives. More importantly, the present invention can solve the phenomenon of protein self-activation. By changing to liquid screening, known protein interaction information can be successfully obtained, which provides a new opportunity for protein-protein interaction research.

Abstract: Provided are an anti-CLDN6 antibody or an antigen-binding fragment thereof; a nucleic acid molecule encoding same; an immunoconjugate, a bispecific molecule, a chimeric antigen receptor and a pharmaceutical composition containing same; and the use thereof for preventing and/or treating tumors.

Abstract: The irregularly-shaped display panel comprises a plurality of pixel units arranged in an array and a shielding layer. some of the pixel units are shielded by the shielding layer to form irregularly-shaped pixel units, and each of the irregularly-shaped pixel unit at least comprises a first irregularly-shaped pixel unit; in the first irregularly-shaped pixel unit, the areas of opening regions of at least two sub-pixels shielded by the shielding layer are different, and the sub-pixel having a larger area of an opening region shielded by the shielding layer has a greater pixel pressure difference.

Abstract: The irregularly-shaped display panel comprises a plurality of pixel units arranged in an array and a shielding layer. some of the pixel units are shielded by the shielding layer to form irregularly-shaped pixel units, and each of the irregularly-shaped pixel unit at least comprises a first irregularly-shaped pixel unit; in the first irregularly-shaped pixel unit, the areas of opening regions of at least two sub-pixels shielded by the shielding layer are different, and the sub-pixel having a larger area of an opening region shielded by the shielding layer has a greater pixel pressure difference.

Abstract: The present invention relates to a reactive polyurethane prepolymer composition, which can be used as a hot melt adhesive, comprising a first polyurethane prepolymer which is the reaction product of the reaction of methylene diphenyl diisocyanate (MDI) with poly(1,6-hexamethylene adipate) glycol (PHAG) with a molecular weight (Mw) of 500 g/mol to 10,000 g/mol and with an NCO content of 0.5 wt % to 7 wt %, preferably of 3 wt % to 7 wt % and more preferably of 5 wt % to 7 wt %, comprising less than 0.1 wt % free MDI monomer based on the total weight of the first polyurethane prepolymer, a second polyurethane prepolymer which is the reaction product of the reaction of methylene diphenyl diisocyanate with polypropylene glycol (PPG) or a succinic acid based polyester polyol with a molecular weight (Mw) of 250 g/mol to 4,000 g/mol and with an NCO content of 0.5 wt % to 12 wt %, preferably of 3 wt % to 11 wt % and more preferably of 5 wt % to 10 wt %, comprising less than 0.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a matrix metallopeptidase 7 (MMP7) gene. The MMP7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MMP7 gene. Pharmaceutical compositions that include one or more MMP7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MMP7 RNAi agents to pulmonary cells, in vivo, provides for inhibition of MMP7 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as idiopathic pulmonary fibrosis (IPF).